Epidemiology of genitourinary melanoma in the United States: 1992 through 2012

Vyas, Ritva; Thompson, Cheryl L.; Zargar, Homayoun; Selph, Jacqueline; Gerstenblith, Meg R.

doi:10.1016/j.jaad.2015.10.015

Cited by 27 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Female genitourinary tract melanoma (FGTM) is rare, accounting for 3% of all melanoma [1] Survival Epidemiology and End Results (SEER) data shows 817 new genitourinary tract melanoma cases between 1992 and 2012 [2]. Among these cases, female genital tract is the most common site (89.4%) followed by male genital tract (6.6%) and urinary tract (4.3%) melanoma.…”

Section: Introductionmentioning

confidence: 99%

Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience

Saglam¹,

Naqvi²,

Zhang³

et al. 2018

Melanoma Research

View full text Add to dashboard Cite

Female genitourinary tract melanoma (FGTM) is a rare and often-fatal form of mucosal melanoma. We describe our institutional experience with 55 cases of FGTM, 16 of which were evaluated with next-generation sequencing targeting 151 cancer-associated genes. Tumors tended to be thicker than conventional melanoma at presentation (median: 3.2 mm), were frequently ulcerated (50%), and characterized by incomplete initial resections. Regional lymph nodes showed tumor involvement at presentation in 28% of cases. With a median follow-up of 23.6 months, the median recurrence free survival was 14.5 months and the median overall survival was 29.6 months. Genomic analysis revealed mutually exclusive mutations in TP53 and KIT in 25%, while 19% of cases showed BRAF mutation. NRAS mutation was found in 13% of cases. Mutation in ATRX, previously undescribed in mucosal melanoma, was seen in three (10%) of 16 patients. Only invasive melanoma cases were included in statistical analyses. Patients with three or more mutations had marginally worse overall survival rates than those with two or less (P=0.07). Further studies are required for potential adjuvant treatment modalities to improve survival outcomes of FGTM.

show abstract

Section: Introductionmentioning

confidence: 99%

Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience

Saglam¹,

Naqvi²,

Zhang³

et al. 2018

Melanoma Research

View full text Add to dashboard Cite

show abstract

“…Because of poor prognosis, early diagnosis is essential, and clinicians need to include it in their differential diagnosis when working up a patient with genitourinary complaints [18]. Microscopic examination of urethral MMs demonstrates a wide histologic spectrum with diffuse, nested, fascicular and storiform patterns of pleomorphic cells [10]. The histopathological diagnosis can be assisted by the use of immunohistochemical markers, such as HMB-45 and S-100.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, vulva contains a relatively high concentration of melanocytes, so it may be the reason for higher incidence of MM in females, than in males (3 : 1) and for the occurrence of 8% at the distal urethra and the meatus [7][8][9]. The most common symptoms are urethral mass, dysuria, hematuria, local or vaginal bleeding and incontinence [10]. Primary urethral MM has a very poor prognosis due to delayed diagnosis and Summary Introduction.…”

Section: Introductionmentioning

confidence: 99%

Primary malignant melanoma of the female urethra − a case report

Hadži-Djokić

Vasić

Bašić³

et al. 2018

Med pregl

View full text Add to dashboard Cite

Introduction. Malignant melanoma accounts for 3% of all cancers in Europe. Malignant melanoma of the genitourinary tract is very rare, accounting for 1% of all cases. In addition, primary malignant melanoma of the urethra accounts for 0.2% of all melanomas and 4% of all urethral cancers. The abnormal migration of melanocytes during the embryonic development may explain their occurrence in the urethra. Also, vulva contains a relatively high concentration of melanocytes, so it may be the reason for higher incidence of malignant melanomas in females than in males, especially located at the meatus or in the distal urethra. Case Report. A 60-year-old woman presented with a solid tumor protruding through the vaginal introitus. Computerized tomography revealed a 5 cm large tumor of the urethra, infiltrating the bladder neck and the anterior vaginal wall. In addition, a bilateral pelvic lymphadenopathy was observed. The patient underwent anterior pelvic exenteration with urethrectomy, bilateral pelvic lymphadenectomy and bilateral ureterocutaneostomy, followed by immunochemotherapy. Nonetheless, the patient died 10 months after the surgery. Conclusion. Urethral melanoma is a tumor with a very poor prognosis and high recurrence rate (71%), even after wide surgical resection, adjuvant radiotherapy, chemo and immunotherapy.

show abstract

“…Так, по данным SEER, за 20-летний период (с 1992 по 2012 г.) был зарегистрирован 721 случай меланомы вульвы, влагалища и шейки матки (521, 186 и 14 больных соответственно) [5]. Отмечена связь возникновения меланомы нижнего женского полового тракта с расовой принадлежностью (количество случаев на 1 млн женщин): 0,87 -у чернокожих; 0,75 -у белых американцев; 1,03 -у азиатов и жителей тихоокеанских островов; 1,22 -у латиноамериканцев; 1,90у не латиноамериканцев [6].…”

Section: обзорные статьиunclassified

“…Меланома шейки матки является чрезвычайно редкой злокачественной опухолью. По данным SEER, за период с 1992 по 2012 г. зарегистрировано 14 случаев первичной меланомы шейки матки, что составило 1,84 % всех выявленных меланом женского полового тракта [5]. Средний возраст больных составляет 50-60 лет; так, в обзоре S. Pusceddu и соавт.…”

Section: обзорные статьиunclassified